By Nanobiotix
Redefining the way drugs are designed and developed Our Curadigm Nanoprimer Platform leverages industry-first nanotechnology to disrupt the design and development of drugs that circulate in the blood, including next-generation precision medicines (e.g. gene therapies, RNA/DNA based therapies, oncolytic viruses, etc.), by solving the problem of therapeutic clearance by the liver.
First-in-class nanoradioenhancer NBTXR3, is designed to increase the dose of radiotherapy that is absorbed and deposited into tumor cells without increasing the dose in surrounding healthy tissues, thereby destroying the target tumor and priming the immune response attack on metastatic tumors. By significantly increasing the tumor-killing effect of radiotherapy without increasing damage to normal tissue, NBTXR3 offers potential to address the unmet needs of millions of patients with cancer. Administration: Administered via one-time injection directly into a malignant tumor prior to standard ionizing radiotherapy Frequency: Scale Hafnium Oxide Core: The unique physical properties of NBTXR3 enable more radiation to accumulate locally within cancer cells Once activated, NBTXR3 increases the energy deposited by radiotherapy within injected tumor cells up to 9 times compared to radiotherapy alone. Clinical data suggest that the mechanism of action of NBTXR3 ultimately induces significant tumor cell death without increasing the damage to surrounding healthy tissues. Because NBTXR3 nanoparticles return to their inactive state after each exposure to radiation, multiple courses of radiotherapy can be administered to a tumor after it has received a single injection of NBTXR3. NBTXR3 is designed to significantly increase the energy deposited by radiotherapy within tumor cells to induce significant tumor cell death without increasing damage to surrounding healthy tissues.
CATEGORY
